Otolaryngologist, head and neck surgeon Francis T. Hall discusses the evaluation of thyroid nodules, which primarily aims to determine the likelihood of malignancy. He then reviews the treatment of thyroid nodules and thyroid cancer, including recent advances in management
Having compliance problems with insulin?
Having compliance problems with insulin?

Kia ora and welcome to New Zealand Doctor Rata Aotearoa
Not a subscriber? Unlock this article by subscribing here.
- https://www.health.govt.nz/your-health/conditions-and-treatments/diseases-and-illnesses/diabetes
- Meneghini L. Demonstrating strategies for initiation of insulin therapy: matching the right insulin to the right patient. Int J Clin Pract 2008;62(8):1255-64.
- Hayes R, Fitzgerald J, Jacober S. Primary care physician beliefs about insulin initiation in patients with type 2 diabetes. Int J of Clin Pract 2008;62(6):860-8.
- New Zealand Guidelines Group (NZGG). Guidance on the management of type 2 diabetes. NZGG, 2011. Available from: www.nzgg.org.nz/practice-tools/diabetes (Accessed Dec, 2011)
- Instructions for Patient Use. Valeritas; 2011.
- Carls GS, Tuttle E, Tan RD, et al. Understanding the gap between efficacy in randomised controlled trials and effectiveness in real-world use of GLP-1 RA and DPP-4 therapies in patients with type 2 diabetes. Diabetes Care. 2017;40:1469-1478.
- Bohannon N, Kelman A, Leichter S, et al. Patient perceptions of the V-Go insulin delivery device. ADA 69th Scientific Sessions; June 5-9, 2009; New Orleans, LA. PO-1993.
Important Risk Information: Always read the label and use only as directed. If regular adjustments or modifications to the basal rate of insulin are required in a 24-hour period, or if the amount of insulin used at mealtimes requires adjustments of less than 2-Unit increments, use of the V-Go Insulin Patch Pump may result in hypoglycaemia. The following conditions may occur during insulin therapy with V-Go: hypoglycaemia (low blood glucose) or hyperglycemia (high blood glucose). Other adverse reactions associated with V-Go use may include skin irritation from the adhesive pad or infections at the infusion site. V-Go should be removed before any magnetic resonance imaging (MRI) testing. A healthcare professional should be consulted to see if this product is right for the patient. V-Go is a registered trademark of Valeritas, Inc.© 2018 Valeritas, Inc. Distributed in New Zealand by NZMS Diabetes, 2a Fisher Crescent, Mt Wellington, Auckland.